Immunic, Inc.

NASDAQ:IMUX

Biotechnology

Healthcare
$7.39 -0.28%

-$0.04 today

Market cap
$100.83M
Beta
1.39
P/E (TTM)
-4.1
EPS (TTM)
-$3.46
52W Low $5.06High $15.77

Volume 0.39M

Average 0.27M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$85.81M

FY 2025 · Annual

Investing Cash Flow

-$161,000.00

FY 2025 · Annual

Financing Cash Flow

$65.58M

FY 2025 · Annual

-12.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(92.95M)(120.41M)(93.61M)(100.51M)(97.17M)
Depreciation & Amortization85K77K111K134K168K
Deferred Income Tax4.33M0000
Stock-Based Compensation5.95M7.93M7.1M8.53M8.86M
Change in Working Capital(9.28M)9.53M15.05M564K1.84M
Accounts Receivables00000
Inventory00000
Accounts Payables176K799K817K3.15M1.24M
Other Working Capital(9.46M)8.73M14.23M(2.58M)601K
Other Non-Cash Items8.63M37.73M523K6.52M497K
Operating Cash Flow(83.23M)(65.14M)(70.83M)(84.77M)(85.81M)
Capital Expenditures(67K)(112K)(334K)(264K)(161K)
Acquisitions (Net)00000
Purchases of Investments0(9.63M)000
Sales of Investments009.8M00
Other Investing Activities00000
Investing Cash Flow(67K)(9.74M)9.46M(264K)(161K)
Debt Repayment00074.27M0
Common Stock Issued42.75M39.58M853K191K65.58M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities92K187K180K77K0
Financing Cash Flow42.84M95.76M1.03M74.54M65.58M
Effect of Forex Changes(130K)(993K)262K(517K)205K
Net Change in Cash(40.59M)19.88M(60.07M)(11.01M)(20.19M)
Free Cash Flow(83.3M)(65.26M)(71.16M)(85.03M)(85.97M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$97.2M
+ D&A$168.0K
+ Stock-Based Comp$8.9M
+ Deferred Tax$0
+ Working Capital$1.8M
+ Other Non-Cash$497.0K
= Operating Cash Flow-$85.8M
- Capex-$161.0K
= Free Cash Flow-$86.0M

Analysis

FY2025 free cash flow is -$86.0M. FCF conversion is 88.5% of net income. Operating cash flow was -$85.8M, with capex of -$161.0K. The largest bridge item is Stock-Based Comp at $8.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
10-QQuarterly reportNov 13, 2026
8-KCurrent reportNov 13, 2026
8-KCurrent reportNov 5, 2026
SC 13G/ASC 13G/A filingNov 2, 2026

Does IMUX generate free cash flow?

Immunic, Inc. (IMUX) generated -$85.97M of free cash flow in fiscal 2025.

How much operating cash flow does IMUX produce?

Operating cash flow was -$85.81M, before capital expenditures of $161,000.00.